We used immunolocalization and in situ hybridization to determine the distribution ofSP-A and SP-A " A in lungs of human fetuses and normal newborn infants. Early in the second fetal trimester a few immunostained cells were observed in tracheal epithelium, often in mucosal folds near the origin of submucosal gland ducts. Non-mucous tracheal gland cells were immunostained for SP-A as they became diffetentiated. Expression of SP-A mRNA was similar to that of immunolocalization in the second trimester. Immunostained cells and SP -A mRNA also appeared about the same time in gestation in isolated cells of bronchial epithelium and glands. SP -A mRNA was seen in bronchiolar cells and pre-lype I1 cells lining terminal airways of fetuses at 19-20 1989;66:1336 44. Williams MC, Hawgood S, Hamilton RL. Changes in lipid structure produced by surfactant proteins SP-A, SP-B, and SP-C. Am J Respir Cell Mol Biol 1991;5:41 45. Zimmerman PE, Voelker DR, McCormack FX. PaulsrudJR, Martin WJ, 11. 120-kD surface glycoprotein of Pneumocystis cantzii is a ligand for surfactant protein A. J Clin Invest 1992;89:143
Introduction
Human surfactant-associated protein A (SP-A) is an Mr 30,000-36,000 glycoprotein associated with phospholipids in pulmonary surfactant, and is the most abundant surfactant-associated protein in pulmonary lavage. Distinct domains have been demonstrated in the SP-A polypeptide, including an amino-terminal collagen domain, a potential amphipathic helical region, and a carboxyterminal lectin-like domain. A single Asp-linked oligosaccharide moiety is located in the human carboxy-terminal domain (for review see L2). The SP-A molecule undergoes extensive posttranslational modification, including sulfation (3), acetylation (4), hydroxylation of prolines ( 5 ) . and addition of complex polysaccharides (6-8). The Asp-linked oligosaccharide on SP-A is added as a high-mannose precursor that undergoes trimming by glucosidases and mannosidases before sialylation (6, 7, 9) . Lamellar body-rich fractions derived from pulmonary Type I1 cells contains sialylated mature SP -A isoforms that co-migrate with SP -A isolated from pulmonary lavage fluid (9,lO) . SP-A enhances the biophysical properties of sur- weeks of gestation. Only in livebom infants did cells of bronchioloalveolar portals and mature Type 11 cells contain SP -A mRNA or immunostain for SP-A. In postnatal infants, luminal material was also stained for SP-A. Although some alveolar macrophages contained immunoreactive material, SP-A mRNA was never detected. The abundance of SP-A in tracheal and bronchial glands and epithelium of conducting airways supports the importance of non-surfaaantassociated functions for SP-A and may be related to a role in host defense. (JWstocbem Cytocbem 41:l311-1.? 19, 1993) KEY WORDS: Blood group A; Immunohistochemistry; In situ hybridization. factant lipids obtained by organic solvent extraction of lung surfactant (1 1,12) . It organizes phospholipids in a calcium-dependent manner (13) and, in the presence of surfactant protein B, calcium, and phospholipids, forms tubular myelin (14) . SP -A also enhances phospholipid uptake and inhibits phospholipid secretion by Type I1 epithelial cells in vitro (15-17). SP-A potentiates the antibacterial functions of alveolar macrophages, suggesting that it acts as an opsonin (18-20). In addition, the lectin-like properties of SP-A may provide an important non-immune mechanism for control of airway infection (21,22). Previous in situ studies have shown that SP-A mRNA is expressed in human alveolar Type I1 cells (23,24). In addition, human bronchial epithelial cells and glands (25) and, in some species, bronchiolar epithelial cells, have shown SP-A by immunohistochemistry (24,26), although this remains controversial.
Human SP-A has recently been shown to contain blood group A antigenic determinants (27). Because polyclonal antibodies raised against SP-A and specific monoclonal antibodies (MAb) react to this blood group antigen, we deglycosylated the SP -A protein and used the remaining moiety for antibody production. This antibody, designated 63742, was absorbed against antigens of the four major human blood groups to further ensure that antibodies against blood group antigenic components had been removed.
This study compares the ontogeny and cellular distribution of this modified SP -A and SP -A mRNA with immunohistochemistry and in situ hybridization in a series of lungs and tracheas from human fetuses and from infants of later gestational ages that died postnatally from non-pulmonary causes.
Materials and Methods

Tissue Preparation
Lung tissue for immunohistochemistry was from 38 normal fetuses (gestational age 10-23 weeks) and from 13 newborn infants dying from nonpulmonary causes (gestational age 25-42 weeks, survival time 5-12 days). Tracheas were available from 18 fetuses and five newborns. Tissues were obtained with parental consent at hysterotomy, hysterectomy, or spontaneous abortion when the fetus was known to be alive during labor, or at postmortem biopsy or autopsy. These studies were approved by the Committee for the Protection of Human Subjects of the Vanderbilt University Medical Center. The postmortem interval before tissue fixation ranged from less than 1 hr to as long as 10 hr. Previous work of Floros et al. (28) demonstrated that tissue harvested within this interval is suitable for study of mRNAs for surfactant apoproteins. Some tissues from stored paraffin blocks were used for immunohistochemistry but were considered inappropriate for in situ hybridization. Lungs from 23 of the fetuses and four newborn infants were used for in situ hybridization studies, as well as 10 fetal tracheas and two newborn tracheas. Tissues were fixed in 10% phosphate-buffered formalin, dehydrated through graded alcohols, and embedded in paraffin. Sections 3-4 pm thick were cut and mounted either on alkylsilanecoated slides (29) or on Superfrost Plus slides (Fisher; Atlanta, GA).
Preparation of Antibody 63 742
Purification of SP-A. Alveolar lavage fluid from a patient with alveolar proteinosis was centrifuged at 10,000 x g. The pellet was re-suspended in a minimal volume of water and injected into a x 5 volume of n-butanol with a &gauge needle. The resulting solution was centrifuged at 20,000 x g for 30 min. then dried under a stream of nitrogen. The dry pellet was re-suspended in an aqueous solution of 10 mM HEPES, 100 mM NaCI, and 20 mM n-octylglucoside (pH 7.4) and centrifuged in Corex tubes at 20,000 x g for 20 mins. Extraction of the pellet with the n-octylglucoside buffer was repeated, and the pellet was re-suspended in 5 mM HEPES (pH 7.4) and dialyzed against the same buffer for 48 hr with at least four changes of buffer. The purity of the protein was tested on a 13% acrylamide gel and the protein concentration determined by the Lowry method (30).
Endoglycosidase Digestion. One mg of purified SP -A was evaporated to dryness in a microphage tube and the pellet dissolved in 100 PI buffer (20 mM sodium phosphate, 10 mM EDTA), 1 pl 10% SDS, and 1 pl P-mercaptoethanol. After boiling for 5 min, 10 p1 endoglycosidase F/Nglycosidase F (Boehringer Mannheim; Indianapolis, IN) was added and the mixture incubated overnight at 37°C. p-elimination. One mg of digested SP-A was evaporated to dryness and reconstituted in 400 p1 H2O. To this was added 400 pl of 0.4 M so-sulfite (pH 11.6) and 12 ~1 0 . 3 M NaOH. After mixing, this was incubated at room temperature for 24 hr. Sixteen pI glacial acetic acid was added and the mixture dialyzed against 5 mM sodium phosphate (pH 7.4) for 48 hr with at least three changes of buffer. Purity of the digested SP-A was ascertained in a 13% acrylamide gel after silver staining. This sample of SP -A was used for antibody preparation. Antibody Preparation. Antibodies to the digested and P-eliminated SP-A were prepared in rabbits. Serum samples of antibody 63742 were subjected to absorption overnight at 4°C with red blood cells from each of the four major blood groups. The cells were separate by centrifugation and the cell-free serum tested again in an ELISA, where it proved to be active up to a dilution of 50,000. The antibody was further analyzed by immunoblot. Human SP-A and digested and P-eliminated SP-A were separated by SDS-PAGE and the proteins transferred to nitrocellulose and reacted with the antibody generated against deglycosylated SP-A. Antibody 63742 reacted strongly with both glycosylated and deglycosylated isoforms of SP-A.
Histochemistry
Localization of immunoreactive SP -A was carried out by the peroxidase-antiperoxidase (PAP) method of Sternberger (31). Sections were deparaffinized, hydrated, treated with 0.3% H202 in methanol, and exposed to 10% normal swine serum to eliminate nonspecific staining. The primary antibody was applied and allowed to remain overnight at room temperature. After washing, sections were exposed to a swine antiserum to rabbit immunoglobulin, washed again, and treated with horseradish peroxidase coupled to rabbit anti-peroxidase. The peroxidase activity was then localized by reaction with a solution containing 0.05% 3,3',diaminobenzidine and 0.01% H202 and counterstained with hematoxylin. Specificity of immunohistochemical results was tested by exposing adjacent tissue sections to nonimmune rabbit serum in place of the primary antiserum. Tissues known to contain or not to contain the antigen were used as controls.
Ablation Studies. Ablation of pulmonary tissue immunostaining with absorbed antibody 63742 was carried out by incubating sections with purified human SP -A 200 pglml, overnight at room temperature. Lung or tracheal tissue from 10 infants was used, of whom five were blood group A and five were neither A nor AB. Immunostaining of Type I1 cells, Clara cells, macrophages, non-ciliated tracheal or bronchial cells, and non-mucous cells of tracheal or bronchial glands was completely ablated by incubation with SP-A (Figures la and Ib).
In Situ Hybridization
cRNA Probe Preparation. An 862-base fragment of a human SP-A cDNA clone was subcloned into pGEM-7Zftranscription vector (Promega; Madison, WI). This fragment contains almost the entire coding sequence of SP-A and recognizes only SP-A mRNA at 2.15 KB in Northern blot analysis of human lung RNA (32) . The orientation of the subcloned fragment with respect to T7 and SP6 promoters was determined by restriction map analysis and confirmed by Northern blotting. Sense and anti-sense RNA probes were synthesized by in vitro transcription. The reaction mixture conb Figure 1 tained a linearized DNA template, ~'[u-~~S]-UTP, 1000-1500 Cilmmol (NEN; Boston, MA) and the reagents of a transcription kit (Riboprobe Gemini I1 Core System; Promega). Radiolabeled probes were reduced to an average length of 100 bases by limited alkaline hydrolysis (33) , and Separated from unincorporated nucleotides by Sephadex G-50 column duomatography. Before hybridization, probes were sized on denaturing agarose gels.
. (a) Bronchus from the lung of a 23 week fetus. Many non-mucous cells in acini of submucosal glands immunostained for SP-A. (b) Serial section of same field as shown in a. lmmunostaining of non-mucous cells in acini of submucosal glands was ablated by incubation of the primary antibody (anti-SP-A) with SP-A before use. (c) Trachea of a 19-week fetus. Scattered epithelial lining cells are immunostained for SP-A. There is immunostaining of cells in the necks of gland ducts and in the ducts themselves. Non-mucous cells in the acini
In Situ Hybridization. In situ hybridization was performed as described by Pelton et al. (34) , with modifications. Briefly, tissue sections were deparaffinized in xylene (twice for 10 min), rehydrated through a graded ethanol series (100% to 30%), rinsed in 1 x PBS ( 5 min), and post-fixed in a freshly prepared solution of 4% paraformaldehyde in 1 x PBS (20 min). Slides were then rinsed in 1 x PBS (twice for 5 min) and treated with a fresh solution of proteinase K (1 Clglml) in 50 mM %is-HC1, pH 8.0, 5 mM EDTA (30 min at 37%). Slides were then rinsed in 1 x PBS (5 min), refixed in the same paraformaldehyde solution ( 5 min), quickly dipped in distilled water, and acetylated in freshly prepared 0.25% acetic anhydride in 0.1 M triethanolamine (twice for 10 min). Slides were subsequently rinsed in 1 x PBS (5 min), dehydrated through the ethanol series (30% to 100%). and dried in a slide dryer (Oncor; Gaithersburg, MD). Tissue sections were covered with a hybridization solution that contained 2 x lo4 cpmlpl sense or anti-sense probe, 50% formamide, 0.3 M NaCI, 10 mM Tris, pH 8.0, 10 mM NaP04, 0.5 mM EDTA, 1 x Denhardt's, 10% dextran sulfate, 0.2 mglml yeast RNA, and 10 mM MT. Tissue and probe were covered with a siliconized coverslip and hybridized in a humid chamber (overnight at 55'C). After hybridization, coverslips were removed in 5 x SSC (1 x SSC equals 150 mM NaCI, 15 mM sodium citrate), 20 mM P-mercaptoethanol (BME) (1 hr at 50%). Slides were washed in 50% formamide, 2 x SSC, 200 mM BME (20 min at 65"C), rinsed in 1 x TEN (10 mM %is, pH 7.5, 0.5 mM EDTA, 0.5 M NaC1) (twice for 10 min at 37'C). treated with a solution of RNAse A (20 pglml) and RNAse TI (a Ulml) in 1 x TEN (30 min at 37'C). and rinsed again in 1 x TEN (twice for 10 min at 37°C). Slides were then washed in 50% formamide. 2 x Table 1 . Immunoreactive SP-A ana' SP-A mRNA in fetuses (10) (11) (12) (13) (14) (15) (16) (17) (18) SSC, 200 mM BME (20 min at 65"C), in 2 x SSC (twice for 15 min at 65°C). and in 0.1 x SSC (twice for 15 min at 65'C). Slideswere dehydrated through graded ethanols containing 0.3 M ammonium acetate, dried, dipped in 50% Ilford K5 emulsion in 1% glycerol, and dried again. After 10 days of exposure, autoradiographs were developed in Kodak D-19 and counterstained with 0.04% toluidine blue.
Results
Lung tissue was from 38 fetuses of 10-23 weeks' gestation and from 13 infants of 25-42 weeks that died from non-pulmonary causes, whose survival time varied from stillborn to 12 postnatal days. Tracheas were not available on every subject, and bronchi and associated glands were not always present in lung sections. Immunohistochemistry was performed on lungs of all 51 subjects with the antiserum against deglycosylated SP -A, after absorption of blood group antigens. Tracheas were likewise studied in 18 fetuses and five liveborn infants. In situ hybridization studies were carried out on 24 fetuses and on four livebom infants whose tissue was processed promptly after death. In 10 fetuses and two livebom infants, tracheas were also considered suitable for in situ hybridization studies. For presentation, we have arbitrarily divided the fetal population into those of 18 weeks' gestation and younger ( Table 1) and those of 19-23 weeks (Tible 2). Infants of 25-42 weeks' gestation are presented in Table 3 . Table 1 shows that SP -A protein was detected in undifferentiated tracheal epithelium beginning at 13 weeks' gestation. Cells h m unostaining with SP-A antiserum were few and frequently appeared in folds suggesting the origins of putative tracheal glands. Putative tracheal glands were present by 14 weeks, and by 16 weeks some cells were immunostained. SP -A mRNA was not detected in trachea by in situ hybridization in this group. Not all lung sections contained bronchi or bronchial glands, especially in young fetuses. Beginning at 15 weeks' gestation, occasional non-ciliated cells were immunostained for SP -A in bronchi and, by 16 weeks, some cells were hmunostained in putative bronchial glands. SP -A mRNA was detected at similar sites in bronchi and frequently in bronchial glands of fetuses after 16 weeks' gestation (Figures 2a and 2b) . Bronchioles and terminal airways were negative for SP -A protein and SP-A mRNA in these fetuses.
Fetuses of 10-18 Weeks
Fetuses of 19-23 Weeks
Both tracheal and bronchial epithelium and glands contained SP -A by immunohistochemistry, and SP-A mRNA was detected intermittently by in situ hybridization from 19 weeks onward (Figures la, IC, Id, 3a, and 3b; Table 2 ). SP-A mRNA was also intermittently present in non-ciliated cells of developing columnar celllined bronchioles beginning at 19 weeks (Figures 4a and 4b) . However, non-ciliated cells in this location were never immunostained with this antibody to SP-A. As cuboidal cell-lined terminal airways began to be invaded by capillaries and to differentiate, both SP -A mRNA and faint immunohistochemical signal for SP -A were detected in cells of the terminal airways (Figures le, Sa, and 5 b) . 
Infants of 25-42 Weeh
In the infants of 25-42 weeks gestation ody five tracheas were a dable and, with one exception, the epithelium of each was severely damaged (Table 3 ). This exception, a 26-week stillborn infant, had cells in deep mucosal folds that immunostained for SP -A. All five had immunostained cells in tracheal glands. Only two tracheas in this group were considered suitable for in situ hybridization studies. SP -A mRNA was present in non-mucous epithelial cells of one trachea and in the tracheal glands of both infants. In sections con-taining bronchi, non-ciliated cells were immunostained for SP -A at 40 weeks' gestation. Bronchial gland cells, when present, were immunostained, with one exception. Only two infants whose lungs were studied with in situ hybridization had bronchial glands in lung sections, and one contained SP-A "A.
SP-A and SP-A
mRNA were detected in bronchiolar non-ciliated cells in t h i s group of infants after 38 weeks ( Figure If) . Mature Type I1 cells were immunostained from 33 weeks onward ( Figure Ig) . SP-A mRNA was detected at 36 weeks in mature Type I1 cells (Figures 6a and 6b ). Before this gestational age, this material was not considered suitable for in situ hybridization studies. Only after 36 weeks' gestation, with the development of terminal airways lined with Type I epithelium opening from cuboidal cell-lined respiratory bronchioles via the bronchioloalveolar portals, did portal cells regularly show positive immunohistochemical signal for SP-A ( Figure 1h ) and in situ signal for SP-A mRNA. Immunostained macrophages were present in four of the liveborn infants and immunostained luminal material in most of the infants. Macrophages did not contain SP-A mRNA.
Table 3. Immunoreactive SP-A and SP-A mRNA in newborn infants (25-42 w e e h of zestation)"
Discussion
We have demonstrated previously that human SP-A isolated from bronchoalveolar lavage contains blood group A antigenic determinants (27). A number of previous studies have demonstrated SP-A in specific cells of lung in human fetuses and adults of unknown blood type (23-25,35,36) and in a number of animal species whose tissues contain blood group A antigen (26,37). Since immunohistochemical identification of SP-A in biologic samples and tissues may be influenced by the presence of blood group- dependent antigenic sites, we used a deglycosylated SP-A antigen to raise antibodies in rabbits. These antibodies were then absorbed by red cells of all four major blood groups. This modified antibody was used to immunostain tracheal and lung tissue from human fetuses and newborns and the results compared with in situ hybridization identification of SP -A mRNA in tissues selected as suitable for this methodology. As with many developmental markers, the respiratory tract develops from cephalad to caudad (38) . Beginning early in the second trimester, a few immunostained cells appeared in tracheal epithelium, most frequently in the depths of mucosal folds where tracheal glands arose. The number of immunostained tracheal epithelial cells diminished as differentiation into ciliated and goblet cells proceeded. This was followed by immunostaining of nonmucous cells of tracheal glands as they became differentiated. SP-A mRNA was seen in both of these locations later in the second trimester. Immunostained cells and SP -A mRNA also appeared at about the same time in bronchi and bronchial glands. SP-A mRNA was present in bronchiolar non-ciliated cells at mid-trimester but they immunostained for SP-A only in mature infants. SP-A mRNA was detected in cells lining terminal airways (pre-Type I1 cells) which were also immunostained for SP-A from 2 0 weeks onward. Pre- Type I1 cells are considered precursors of mature Type I1 cells and of Type I cells, either by further differentiation of Type I1 cells or directly from pre-Type I1 cells. In live-born infants, cells of the bronchioloalveolar portals or mature Type I1 cells showed SP-A mRNA and immunostaining for SP-A as septation proceeded and true acini developed. In these infants, immunostained luminal material was frequently found and some infants had immunostained macrophages, none of which demonstrated SP-A mRNA. and their immunostained contents are presumed to be the result of phagocytosis.
The presence of SP-A or SPA mRNA has not been demonstrated previously in tracheal epithelium or tracheal submucosal glands. In none of the previous studies using human fetal or adult material were tracheas or tracheal glands examined (23-25, 35, 36) . Our findings of cells immunostained for SP-A in bronchi and bronchial glands agree with the recent study of eight fetuses and three adult lungs reported by Endo and Oka (25). Using an MAb to SP -A (PE10). these authors demonstrated immunostaining of bronchial epithelial cells and, in two fetuses, bronchial glands. In situ hybridization studies were not included. Previous in situ studies of adult human surgical specimens have shown SP-A mRNA only in Type I1 cells. Bronchi and glands were not described (23,24). The present study detected SP-A mRNA in bronchiolar non-ciliated cells at mid-trimester, these cells being immunostained for SP-A only in mature infants. Pre-Type I1 cells were not observed by Endo and Oka (25) as early as in our material. Both Clara cells and Type I1 cells in rodents contain SP-A as well as SP-A mRNA (24.26). Rodent lungs do not have bronchial submucosal glands and rodent tracheas have not been described in immunohistochemical studies of SP-A or SP-A mRNA. However, we have observed immunohistochemical staining of non-mucous cells of rat tracheal submucosal glands for deglycosylated SP -A (Stahlman, Gray, personal communication).
The discrepancies in appearance times of SP -A and SP -A "As detected by immunohistochemistry and by in situ hybridization studies might be explained in several ways. The later appearance of SP -A than SP -A mRNA might be expected, as was the case with cells in bronchi and ciliated bronchioles. The earlier appearance of SP-A than of SP-A mRNA that occurred in tracheal epithelium and tracheal glands is most likely due to the fact that none of the tracheal tissue was taken at lung biopsy obtained within 2 hr after death, and was available only at autopsy several hours later. The E production by tracheal and bronchial glands may exceed that of terminal airways. This may be reversed in late fetal development and in the newborn as septation occurs, Type I1 cells mature, and alveoli continue to proliferate while tracheal and bronchial glands remain relatively fixed in number. This suggests that SP-A produced in these sites has a role unrelated to the regulation of production or recycling of surfactant phospholipids (15) (16) (17) 42, 43) , a role in their surface tension-lowering properties, or in formation of tubular myelin (13) (14) (15) 44) . SP-A potentiates the anti-bacterial functions of alveolar macrophages suggesting that it acts as an opsonin (18-20). SP-A is one of a family of mannose-binding proteins believed to specifically bind certain organisms, such as Group B P-hemolytic streptococci and Pneumocystis carinii, which have oligosaccharides in their surface membranes or capsular material (22,45). In contrast to the strong signal for SP-A in conducting airway epithelium and glands, the immunohistochemical signal for SP-A in mature Type I1 cells was less intense, and lamellar bodies appeared unstained. This might be due in part to tissue processing. The abundance of SP-A in tracheal and bronchial glands and in epithelium of airways at all levels of the lung may support the concept that SP-A, perhaps through its lectin-like properties (21,22), provides an important non-immune mechanism for control of airway infection. preservation of the mRNA in this material might therefore have been less optimal than that of the SP-A protein. In addition, there may have been differences in the ability of the two techniques to detect the same strength of signal, depending on such things as antibody titer and length of radioautography.
The appearance of SP-A and SP-A mRNA in pre-Type I1 cells of developing terminal airways often coincided with the history of PROM, and frequently with the presence of a few polymorphonuclear leukocytes in terminal airways. This suggests stimulation of Type I1 cell differentiation and SP-A gene expression by endotoxin-induced prostaglandins, a mechanism previously shown in lung explants (39) (40) (41) . Types of nonspecific stress other than PROM have been shown to be associated with stimulation of Type I1 cell differentiation assumed to be associated with steroid production.
We have shown that before differentiation of terminal airway epithelial cells, SP-A can be detected in tracheal and bronchial epithelial cells, primarily in the depths of mucosal folds, followed by its appearance in cells of the necks and ducts of submucosal tracheal and bronchial glands and in groups of non-mucous cells in the glands themselves. At this stage of fetal development, SP-A Literature Cited
